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Energy metabolismHypertrophic cardiomyopathy is a typical manifestation of very long-chain acyl-CoA dehydrogenase deﬁciency
(VLCADD), themost common long-chainβ-oxidation defects in humans; however in some patients cardiac func-
tion is fully compensated. Cardiomyopathy may also be reversed by supplementation of medium-chain triglyc-
erides (MCT). We here characterize cardiac function of VLCAD-deﬁcient (VLCAD−/−) mice over one year.
Furthermore, we investigate the long-term effect of a continuous MCT diet on the cardiac phenotype. We
assessed cardiac morphology and function in VLCAD−/−mice by in vivo MRI. Cardiac energetics were mea-
sured by 31P-MRS and myocardial glucose uptake was quantiﬁed by positron-emission-tomography (PET).
Metabolic adaptations were identiﬁed by the expression of genes regulating glucose and lipid metabolism
using real-time-PCR. VLCAD−/−mice showed a progressive decrease in heart function over 12 months ac-
companied by a reduced phosphocreatine-to-ATP-ratio indicative of chronic energy deﬁciency. Long-term
MCT supplementation aggravated the cardiac phenotype into dilated cardiomyopathy with features similar
to diabetic heart disease. Cardiac energy production and function in mice with a β-oxidation defect cannot
be maintained with age. Compensatory mechanisms are insufﬁcient to preserve the cardiac energy state
over time. However, energy deﬁciency by impaired β-oxidation and long-termMCT induce cardiomyopathy
by different mechanisms. Cardiac MRI and MRS may be excellent tools to assess minor changes in cardiac
function and energetics in patients with β-oxidation defects for preventive therapy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hypertrophic cardiomyopathy and arrhythmias are typical manifes-
tations of the severe early-onset phenotype of very-long-chain acyl-CoA
dehydrogenase deﬁciency (VLCADD) [1], the most common disorder of
the mitochondrial long-chain fatty acid oxidation (mFAO) pathway [2].
Especially in situations of increased energy demand, VLCAD-deﬁcient
patients may undergo severe metabolic derangement leading to life-
threatening events, coma and death [3]. The recommended treatment
includes supplementation with medium-chain triglycerides (MCT) as
partial or complete replacement of the normal long-chain triglycerides
(LCT) [4,5]. Medium-chain fatty acids easily by-pass the ﬁrst step ofiatrics, Center for Pediatrics and
se 1, 79106 Freiburg, Germany.
cci).the mFAO catalyzed by VLCAD andmay be fully metabolized for energy
production. The supplementation with MCT can completely reverse
acute hypertrophic cardiomyopathy in affected patients [6,7]. However,
a continuous MCT diet in asymptomatic patients is widely debated.
The implementation of neonatal screening for VLCADD allowed the
identiﬁcation of an ever increasing number of patients and contributed
signiﬁcantly to an improvement in disease morbidity and mortality. In
fact, some patients remain asymptomatic over long periods of time
also without preventive measures that are usually initiated after posi-
tive screening. Thus, the heart seems to be able to compensate for a de-
fective mFAO by alternative mechanisms of energy production.
Whether these compensatory mechanisms can persist and maintain
their efﬁciency life-long is arguable. To gain insights into the long-
term fate of VLCADD, we explored VLCAD-deﬁcient (VLCAD−/−) mice
[8] presenting with a similar clinical phenotype as humans [9–14].
However, in contrast to humans mice also express an enzyme with
overlapping substrate speciﬁcity, the long-chain acyl-CoA dehydroge-
nase (LCAD). This enzyme has also been described to play an important
role in the murine mFAO pathway especially for the oxidation of long-
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mouse model accumulates the same acylcarnitine species as occur in
VLCADD patients and present with a prominent cardiac hypertrophy
at birth [16].
With regard to the heart, VLCAD−/−mice have been reported to dis-
play an altered calcium homeostasis [17], prolonged QT interval [18] as
well as a mild hypertrophy at three months of age [19] while they
are fully asymptomatic at birth although lacking the complete Acadvl
gene. These characteristics make VLCAD−/− mice an excellent model
for the investigation of pathomechanisms involved in the development
of symptoms caused by the lack of VLCAD long-term. Since follow-up
studies of the cardiac phenotype in adults are still missing and the
chronic effects of a defective mFAO machinery on cardiac function and
morphology are still unknown we monitored cardiac function in vivo
over a period of one year by cine-MRI. In VLCAD−/−mice cardiac energet-
ics were determined by in vivo 2D 31P chemical shift imaging (CSI)
and myocardial glucose uptake was studied by positron-emission tomog-
raphy (PET).Metabolic adaptations under normal and long-termMCTdiet
were investigated by analysis of genes regulating cardiac glucose and lipid
metabolism. Furthermore, cardiac lipid accumulation, markers of oxida-
tive stress as well as the reactivation of the fetal gene program were
examined.2. Materials and methods
2.1. Animals
Experiments were performed on fourth- to ﬁfth-generation inter-
crosses of C57BL6 + 129sv VLCAD genotypes. Littermates served as
controls and genotyping ofmicewas performed as described previously
in Exil et al. [8]. Groups consisting of 10–12mice, at the age of three, six
and 12 months were investigated under well-fed conditions. After the
ﬁnal examination, the mice were sacriﬁced by CO2 asphyxiation and
the heart was rapidly removed and immediately frozen in liquid
nitrogen.
All animal studieswere performedwith the approval of theHeinrich
Heine University Institutional Animal Care and Use Committee and in
accordance with the Committees' guidelines (Landesamt für Natur,
Umwelt und Verbraucherschutz, LANUV, Germany; ﬁle number: 8.87-
50.10.34.09.072).2.2. Diet composition and supplementation
At the age of 5–7 weeks, mice of each genotype were divided in two
groups and fedwith different diets for one year. The ﬁrst group received
a normal puriﬁedmouse diet containing 5% crude fat in the form of LCT,
corresponding to 12% of metabolizable energy as calculated with Atwa-
ter factors (ssniff® EF R/M Control, ssniff Spezialdiäten GmbH, Soest,
Germany). The second group was fed with a diet corresponding as
well to 12% of total metabolizable energy. Here, 4.4% from a total of
5% fat was MCT (Ceres®MCT-oil, basis GmbH, Oberpfaffenhofen,
Germany) while the remaining 0.6% was derived from soy bean oil
to provide the required essential long-chain fatty acids. The content of
essential long-chain fatty acids was calculated in accordance with
the Nutrient Requirements of Laboratory Animals (Subcommittee on
Laboratory Animal Nutrition, Committee on Animal Nutrition, Board
on Agriculture, National Research Council). Both diets based on puriﬁed
feed ingredients contained the same nutrient concentration as follows:
94.8% drymatter, 17.8% crude protein (N× 6.25), 5% crude fat, 5% crude
ﬁber, 5.3% crude ash, 61.9% nitrogen free extract, 36.8% starch, 14.8%
dextrin and 11% sugar. The detailed fatty acid composition of the diets
was previously reported [20]. In both diets the carbohydrate and pro-
tein contents corresponded to 69% and 19% ofmetabolizable energy, re-
spectively. All mouse groups received water ad libitum.2.3. Cardiac magnetic resonance imaging and spectroscopy
Data were recorded on a Bruker AvanceIII 9.4 Tesla Wide Bore
(89 mm) nuclear magnetic resonance (MR) spectrometer operating at
frequencies of 400.13MHz for 1H and 161.97MHz for 31P measurements
as previously described [21]. Experimentswere carried out using aBruker
microimaging unit (Mini 0.5) equipped with actively shielded gradient
sets (capable of 1 T/m maximum gradient strength and 150 μs rise
time at 100% gradient switching), a dual tunable 1H/31P 30-mm birdcage
resonator, and Paravision 5.1 as operating software. Themice were anes-
thetizedwith 1.5% isoﬂurane andwere kept at 37 °C. For functional anal-
ysis, high resolution images ofmouse heartswere acquired using an ECG-
and respiratory-triggered fast gradient echo cine sequences. A ﬂip angle
of 25°, echo time of 1.8 ms, and a repetition time of about 4 ms were
used. The pixel size after zero ﬁlling was 117 × 117 μm2 (ﬁeld of view,
30 × 30 mm2; matrix, 128 × 128; acquisition time per slice for one cine
sequence, 1–2 min). Six to eight contiguous ventricular short axis slices
(slice thickness 1 mm) were acquired to cover the entire heart.
Subsequently, cardiac high energy phosphates were analyzed using
2D 31P chemical shift imaging (CSI). The slice used for spectroscopic im-
aging (6mm)was placedmid-ventricular in short-axis orientation cov-
ering almost the entire heart from apex to the base. Fieldmap-based
shimming (MAPSHIM) was carried out to optimize the ﬁeld homo-
geneity in the region of interest. The 2D 31P CSI data set was recorded
with a sine-bell acquisition-weighted sequence to improve the spatial
response function using the following parameters: ﬂip angle, 45°; repe-
tition time (TR), 250 ms; ﬁeld of view, 30 × 30 mm2; matrix 16 × 16
(voxel size ~ 20 μl); data points in the spectral domain, 1024; spectral
width, 6510 Hz; slice selection with a 500-μs sinc3 pulse; acquisition
time, 75min [21]. An exponential ﬁlter of 20Hzwas applied in the spec-
troscopic direction and chemical shifts were referenced to the PCr reso-
nance at−2.52 ppm. For quantiﬁcation of myocardial PCr/ATP ratios,
only voxels covering the free left ventricular wall were considered,
since in both groups spectra of septal voxels were occasionally contam-
inated with 31P signals originating from chamber blood as reﬂected by
the appearance of 2,3-diphosphoglycerate (DPG) signals (data not
shown).2.4. Positron emission tomography (PET) imaging
F-18-ﬂuordeoxyglucose (FDG, 10 MBq) in 100 μl 0.9% saline was
injected intraperitoneally without anesthesia since this would have
had effects on blood insulin and glucose levels. After 1 h of tracer distri-
bution animals were anesthetized with isoﬂurane (1.5–2.0%) and
placed on a heating pad to maintain the body temperature. PET list
mode data was acquired for 15 min using the 32-module quadHIDAC
scanner (Oxford Positron Systems, Weston-on-the-Green, UK) dedicated
to small animal imaging. The scanner has an effective resolution
of 0.7 mm (FWHM) in the transaxial and axial directions when using
an iterative resolution recovery reconstruction algorithm. PET data
were reconstructed into a single image volume for each mouse with a
voxel size 0.4 × 0.4 × 0.4 mm3. Quantiﬁcation of segmental tracer uptake
and volumes of the left ventricle was performed using in-house software
programmed inMATLAB (TheMathworks) andCprogramming languages
[22].2.5. Tissue homogenates
Tissues were homogenized with Cellytic MT Buffer (Sigma-Aldrich,
Steinheim, Germany) in the presence of 1 mg ml−1 protease inhibitors
and centrifuged at 4 °C and 16,000 g for 10 min to pelletize any cell de-
bris. The clear supernatantwas immediately used for the enzyme assays
or stored at−80 °C. Protein concentration of tissue homogenates was
determined using the BSA method as previously described [23].
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Fig. 1. Time course of cardiac function of WT and VLCAD−/−mice under control diet. A) Representative short-axis 1H-MR images in end-diastole and end-systole of WT and VLCAD−/−
mice at the age of 12 months. B) End-diastolic and end-systolic volumes at the age of 3, 6 and 12 months. C) Stroke volume and ejection fraction at the age of 3, 6 and 12 months. * in-
dicates signiﬁcant differences betweenWT and VLCAD−/−mice (n= 10–12).
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substances (TBARS), reduced glutathione (GSH) and protein carbonylation
degree
Cardiac TAGwere extracted from lyophilized tissue andmeasured as
duplicates on an InﬁniteM200 Tecan (Crailsheim, Germany) plate read-
er as previously reported [14]. All assays were performed following the
manufacturer's instructions. Themeasurement of TBARSwasperformed
as previously described [13]. GSH was measured with the Glutathione
Assay Kit (Cayman Chemical, Ann Arbor, USA). Measurement of protein
carbonylation was performed with the Protein Carbonylation Assay Kit
(Cayman Chemical, Ann Arbor, USA).2.7. Measurement of pyruvate kinase (PK) activity, ketone bodies and
lactate
PK activity was performed in duplicate using the Pyruvate Kinase
Assay Kit (BioVision, Mountain View, USA) as recommended by the
manufacturer's instruction. Ketone bodies were measured with a Preci-
sion Xceed blood sugar meter (Abbott, Wiesbaden, Germany). Measure-
ment of lactate was performed using the Lactate Assay Kit (Sigma-
Aldrich, Steinheim, Germany) following the manufacturer's instructions.2.8. RT-PCR analysis
Total RNA from heart was isolatedwith the RNeasymini kit (Qiagen,
Hilden Germany). Forward and reverse primers were designedwith the
FastPCR program (R. Kalendar, Institute of Biotechnology, Helsinki).
Gene function and primer sequences are reported in Supplemental
Table 1. RT-PCR was performed in a single step procedure with the
QuantiTect SYBR Green™ RT-PCR (Qiagen, Hilden, Germany) on an Ap-
plied Biosystems 7500 Real-Time PCR-System (Applied Biosystems,
Foster City, CA, USA). β-Actin was used as reference gene.2.9. Statistical analysis
MRI data are reported asmean values± standard deviation (SD). All
other data are presented asmeans± standard error of themean (SEM).
n denotes the number of animals tested. Analysis for the signiﬁcance
of differences was performed using Student's t-tests for paired and un-
paired data and Wilcoxon-Signed-Rank Test. To test the effects of the
two variables, diet and genotype, two-way analysis of variance
(ANOVA) with Bonferroni post-test was performed (GraphPad Prism
5, San Diego California USA). Differences were considered signiﬁcant if
p b 0.05.
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3.1. Progressive development of systolic dysfunction in VLCAD−/−mice
The long-term effects of a defective mFAO on cardiac function in
VLCAD−/− mice were analyzed in WT and mutants under a normal
diet at the age of 3, 6 and 12 months by cine 1HMRI. Fig. 1A shows rep-
resentative short-axis MRIs of one year old mice in end-diastole
and end-systole (see also Supplemental Movies 1 and 2). At this age
VLCAD−/− mice exhibited signiﬁcantly increased end-diastolic and
end-systolic volumes (EDV + ESV) resulting in a pronounced
reduction of ejection fraction (EF) as compared to WT mice (58.9 ±
9.5% vs 75.4 ± 4.7%; p b 0.01; n= 10). This functional impairment oc-
curred progressively (Fig. 1B + C), in that EF was already signiﬁcantly
reduced in VLCAD−/−mice at the age of 6months and furtherworsened
in 12 month-oldmice. Nevertheless, stroke volume and thereby cardiac
output remained unaffected (Fig. 1C). Planimetry of themyocardial walls
revealed amild transient hypertrophy in 6 month-old VLCAD−/−mice as
compared to WT controls (end-diastolic wall thickness: 1.08 ± 0.070
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Fig. 2.Myocardial energetics and glucose metabolism in 12 month-old WT and VLCAD−/−mic
spectra (top) as well as myocardial glucose uptake measured by FDG-PET (bottom) inWT and V
over the entire freewall of the left ventricle). C) Glucose uptake determined by in vivo FDG-PET
analyses were performed in 12 month-old mice. * indicates signiﬁcant differences between Wvs 1.00 ± 0.07 mm; p b 0.05). However, these differences were not any-
more observed in one year oldmice, but VLCAD−/−mice displayed a sig-
niﬁcant reduction in systolic wall thickness (1.43 ± 0.23 vs 1.67 ±
0.15 mm; p b 0.05) indicative of systolic dysfunction.
3.2. Impaired myocardial energetics and glucose metabolism in 12 month-
old VLCAD−/−mice
To analyze themetabolic state,weﬁrstmeasuredmyocardial energet-
ics of mutants and littermates at the age of 12 months by 2D-31P-CSI.
Fig. 2A top shows representative 31P-MR spectra extracted from full CSI
data sets of WT and VLCAD−/−mice in correlation with the anatomical
end-diastolic 1H MR image. As can be seen, dilation of VLCAD−/− hearts
(right) is accompanied by a marked decrease of cardiac phosphocreatine
(PCr) levels. Averaging the high energy phosphate levels over posterior,
lateral, and anterior walls revealed a signiﬁcantly decreased PCr-to-ATP
ratio (1.48 ± 0.29 vs. 2.01 ± 0.26; p b 0.05; Fig. 2B) over the entire left
ventricle. The observed effects were caused by a drop in PCr levels since
no differences in ATP levels were detected between the groups.0
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cardial energy state in VLCAD−/−mice was also accompanied by alter-
ations in cardiac substrate metabolism. FDG-PET as noninvasive
measure of myocardial glucose uptake showed in mutants indeed a
higher FDG uptake as compared to WT mice (3.02 ± 0.44 vs 2.01 ±
0.5% ID, Fig. 2A bottom + C). Surprisingly, this did not correspond to an
increased pyruvate kinase (PK) activity which was found to be sig-
niﬁcantly lower in mutant hearts (1.70 ± 0.22 vs 2.36 ± 0.4 mU/mg,
p b 0.05; Fig. 2D). Because of this metabolic decompensation we mea-
sured the expression of genes typically expressed in developing hearts
and down-regulated in adult organs known as genes of the fetal gene
program, namely Acta1, MHCα, MHCβ and Glut4. However, in failing
heart these are again up-regulated to compensate for cardiac metabolic
derangement [24]. Especially Acta1was markedly up-regulated in mu-
tants as compared to WT (315.6 ± 5.7 vs 99.9 ± 1.2%; p b 0.05). In
linewith the decreased PK activity, PDK4, which is known to inhibit glu-
cose oxidation, was signiﬁcantly up-regulated in mutants (308.7 ± 9.4
vs 100 ± 3.8%; p b 0.05; n = 10; see also below), whereas the glu-
cose transporter Glut4 was strongly down-regulated (50.4 ± 12.4
vs 100.5 ± 18.3%; p b 0.05; n = 10; see also below). Of note, we
found no evidence for an altered utilization of alternative substrates,
such as ketone bodies or lactate, in VLCAD−/−mice under control diet
(see below).3.3. MCT diet does not prevent the gradual development of cardiomyopathy
in VLCAD−/−mice
In the next step, we investigated whether a continuous MCT diet
could counteract the observed phenotype. Surprisingly, this diet result-
ed in WT control mice in a signiﬁcant reduction in EF as compared to0.4
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VLCAD−/−mice under different dietary conditions as compared to control diet (n= 10–12).untreated WT (69.41 ± 4.41 vs 75.40 ± 4.71%; p b 0.05; n = 10;
Fig. 3B). Even more critically, in the mutants long-term MCT diet not
only failed to attenuate cardiac dysfunction, but even aggravated thede-
gree of cardiomyopathy as illustrated in representative long-axis MRIs
in Fig. 3A. End-systolic images acquired after one year of diet clearly in-
dicate the exacerbation of systolic dysfunction in VLCAD−/− mice fed
with MCT (see also Supplemental Movies 3–6). Already after 6 months
a reduction in systolic wall thickness was observed in VLCAD−/−mice
fed with MCT compared to mice under control diet (1.47 ± 0.15 vs
1.62 ± 0.36 mm of WT; p b 0.05; Fig. 3C). In mutants treated
with MCT for 12 months, EF was further reduced in comparison with
VLCAD−/− mice under normal diet (52.35 ± 7.49 vs 58.95 ±9.54%;
p b 0.05; n= 10; Fig. 3B). This functional impairment was accompa-
nied by signiﬁcantly reduced systolic and diastolic wall thicknesses
(Fig. 3D). Additional cardiac parameters such as end-systolic and end-
diastolic volumes given in Supplementary Table 1 further strengthened
these ﬁndings.3.4. Impairment of energy metabolism and reactivation of the fetal gene
program
To gain insight into the underlyingmetabolic pathomechanisms, we
analyzed heart homogenates for genes typically expressed during fetal
development. Long-term supplementation with MCT for 12 months
led VLCAD−/− mutants to a dramatic up-regulation of Acta1 as com-
pared toWT under the same dietary regimen (Fig. 4B) indicative of car-
diac stress and accompanied by energy deﬁciency as shown by
in vivo 31P-CSI ﬁndings. Of note, this was not yet observed after
6 months of MCT diet, but interestingly at this point of time Acta1was sig-
niﬁcantly up-regulated inmutants under control diet— but to a substantial0.4
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Fig. 4A + B). In parallel, the down-regulation of Glut4 with a con-
comitant up-regulation of PDK4 under MCT in both groups in mice
at the age of 6 months (Fig. 4A), which persisted up to 12 months
suggested an inhibition of glucose uptake and oxidation.
3.5. Alternative substrates under normal and MCT diet
Since supplementation of MCT is known to elevate circulating levels
of ketone bodies (KB) which may be used as alternative substrates, we
determined KB concentrations in the hearts of one year old mice.
Fig. 5A shows no differences between WT and VLCAD−/− mice under
normal diet. In contrast, as typical effect of MCT both genotypes under
this dietary regimen displayed a markedly higher concentration of KB,
whereas lactate concentration was affected neither by the genotype
nor by the diet (Fig. 5A). In accordance to the increase in KB content,
the expression of cardiac Bdh1 and Acat1 both critically involved in
ketolysis was signiﬁcantly up-regulated suggesting an enhanced use of
KB for energy production under MCT diet in both genotypes (p b 0.05;
Fig. 5B).
3.6. MCT diet induces cardiac lipid accumulation and oxidative stress
Finally, we investigated the effects of both diets on cardiac lipid ho-
meostasis after one year [20]. Triglyceride (TAG) concentrations were
found to be much higher in the hearts of mice under MCT diet (Fig. 6A).
In particular, VLCAD−/−mice showed a signiﬁcantly higher TAG content
as compared to mutants under normal diet (74.01 ± 12.71 vs 44.73 ±
8.41 μmol/g; p b 0.05). In a similarmanner, the concentration of thiobar-
bituric acid reactive substances (TBARS), end products in the degradation
of lipid peroxides, was signiﬁcantly increased in these mice with a two-
fold higher TBARS content as compared to VLCAD−/−mice under normal
diet (4.1 ± 1.0 vs 2.1 ± 0.6 μmol/g; p b 0.05; Fig. 6B). The content of re-
duced glutathione (GSH) was already signiﬁcantly lower in mutants
under normal diet, whereas MCT supplementation led to a further de-
crease of GSH in both genotypes (Fig. 6C). Likewise, tissue levels of
carbonylated proteins were observed to be elevated in mutants under
control diet, and MCT diet signiﬁcantly enhanced oxidative protein car-
bonylation in both genotypes under MCT diet (p b 0.05; Fig. 6D).
Oxidative stress was also documented by the peculiar gene expres-
sion proﬁles of uncoupling proteins UCP2 and UCP3 (Fig. 6E–F) induced
by increased circulating fatty acids as occurred in mice under MCT diet
[20]. At the age of 6 months, when VLCAD−/−mice developed a tran-
sient hypertrophy under normal diet, a strong up-regulation of UCP2
was observed, which has been described as compensatory mechanism
to reduce the electrical potential across the inner mitochondrial mem-
brane avoiding the production of superoxide radicals in the periodprior to heart failure [25]. At that time also UCP3 was signiﬁcantly up-
regulated suggesting the presence of oxidative stress already at this
age (p b 0.05; Fig. 6E). The expression of UCP2 normalized in all groups
at the age of 12 months as reported after heart failure, however, both
genotypes fed with MCT further showed a signiﬁcant up-regulation of
UCP3 expression (p b 0.05; Fig. 6F). This expression pattern of genes
coding for UCP proteins strongly resembles the cardiac phenotype asso-
ciated with diabetic disease [26]. In accordance to a previous report,
PPARα which regulates the availability of fatty acids and the activity of
FAO machinery was down-regulated in VLCAD−/−mice at the age of 6
and 12 months [9] (Fig. 6E–F).4. Discussion
In this study we demonstrate for the ﬁrst time that VLCAD-deﬁcient
mice develop progressive cardiac dysfunction without the trigger of
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tions a chronic and continuous energy deﬁciency leading to pronounced
metabolic and functional cardiac decompensation over time. Although
the beneﬁt of MCT onmetabolically deranged patients with acute cardio-
myopathy has been proven in several clinical studies, we show that the
long-term application of this diet in VLCAD−/−mice could not prevent
the temporal development of cardiac dysfunction but even aggravated
the cardiac phenotype to a diabetic form of dilated cardiomyopathy.
Since non-stressed youngVLCAD−/−micewere described as asymp-
tomatic [11,12,20] we initially hypothesized that an up-regulation of
glucose oxidation together with an increase in oxidative capacity of
long-chain acyl-CoA dehydrogenase (LCAD), a β-oxidation enzyme
with overlapping substrate speciﬁcity, could compensate for lacking
VLCAD oxidation capacity [15,27]. Indeed, glucose uptake in 12 month-
old VLCAD−/−mice was increased as shown by FDG-PET analysis indica-
tive of enhanced glucose ﬂux. On the other hand, the reduction of pyru-
vate kinase activity with a concomitant up-regulation of PDK4
expression and a reduced expression of the gene coding for GLUT4 trans-
porter suggest a down-regulation of the glucose oxidation pathway as
also observed by Lei et al. in the failing dog heart [28,29]. In addition to
that, VLCAD−/−mice display an inverse relationship between enhanced
myocardial glucose uptake and a reduced PCr/ATP ratio similar toprevious reports on cardiac substrate metabolism in hypertrophied
hearts [30,31]. Since VLCAD−/− mice display an expression pattern of
genes typically up-regulated in developing hearts and in adult hearts
solely in cases of functional impairment and metabolic derangement
[32]we hypothesize that despite enhanced glucose ﬂux the overall cardi-
ac energy production is impaired resulting in the development of cardiac
dysfunction over time.
There is recent evidence that inmicewithβ-oxidation defects, under
severe catabolic conditions the accumulation of triglycerides results in
lipotoxicity, which contributes to the onset of arrhythmia and left ven-
tricular dysfunction [18,33]. However, the present investigation was
performed in the well-fed, resting state during which the mutants do
accumulate neither cardiac TAG (Fig. 6A) nor acylcarnitines [34]. There-
fore, lipotoxicity is unlikely to be the predominant mechanism in the
development of cardiomyopathy in VLCAD−/− mice under a normal
diet, in strong contrast to mice supplemented with an MCT diet. Here,
lipotoxicity plays a key role as shown by TAG accumulation and lipid
peroxides in form of TBARS, which clearly represent a link between ox-
idative stress and heart failure as their tissue levels inversely correlate
with the ejection fraction [35,36]. Indeed, not only VLCAD−/− mice
but also WT mice supplemented with a long-term MCT diet displayed
a marked accumulation of TAG and oxidative stress accompanied by a
684 S. Tucci et al. / Biochimica et Biophysica Acta 1842 (2014) 677–685signiﬁcant impairment of cardiac function. These ﬁndings corroborate
our hypothesis of MCT-induced lipotoxicity when applied long-term
during energetic steady state periods independent of the presence of a
mitochondrial fatty acid β-oxidation defect. Similar to the reported
data on the effects of MCT in the liver, the marked reduction of GSH ac-
companied by enhanced protein carbonylation underline the striking
effect of MCT in promoting oxidative stress. These ﬁndings correlate
with the marked expression of the UCP3 gene observed in the hearts
of WT and VLCAD−/− mice after long-term MCT supplementation
(Fig. 6F). Although we did not measure enzyme activities it is reported
that the uncoupling capacity of UCP3 is activated by lipid peroxides, by
decreasing mitochondrial ROS production and reducing their down-
stream detrimental effects [37]. The expression proﬁles of the
uncoupling proteins UCP2 and UCP3 support the fact that oxidative
stress further aggravates cardiac dysfunction under MCT diet. At the
age of 6 months under both dietary regimens, VLCAD−/− mice
displayed higher expression of UCP2. This up-regulation has been re-
ported in the period prior to heart failure to meet the production of su-
peroxide radicals at complex I of the mitochondrial respiratory chain
[25,38]. In contrast, in 12 month-old mutants under both diets the ex-
pression of UCP2 is down-regulated as reported in failing hearts [39]
while mutants at the same age uponMCT strongly expressUCP3 resem-
bling the expression proﬁle of diabetic hearts [26].
MCT supplementation results in a high content of circulating
medium-chain fatty acids in the blood, which may be easily absorbed
by the organs. Furthermore,MCT are highly ketogenicwhich is reﬂected
by increased ketone body production and the enhanced expression of
genes coding for enzymes of the ketolytic pathway (Fig. 5) suggesting
an increased utilization of these substrates in the hearts of both geno-
types. However, higher ketone body concentrations increase the acetyl
CoA/CoA and NADH/NAD ratios within the mitochondria contributing to
the inhibition of the pyruvate dehydrogenase complex by up-regulation
of PDK4 [40,41]. This effect is ampliﬁed by the high free fatty acid content
in blood of VLCAD−/−mice [20] which also impacts on metabolism by
inhibiting glucose uptake and oxidation [42]. Although MCT quickly sup-
ply the organism with metabolizable substrates, in the long-run
glucose oxidation will be inhibited and medium-chain fatty acids will be
converted into long-chain fatty acids aggravating the metabolic state of
VLCAD−/−mice [20,43].
Duringmetabolic derangement, however, the supplementationwith
MCT has been proven to be effective especially in the treatment of the
acute cardiomyopathy and in the prevention of rhabdomyolysis
[6,7,43,44]. In isolated cases Roe et al. [45]. reported on the positive ef-
fect of triheptanoin.
In summary, we demonstrate that under well-fed conditions
VLCAD−/−mice gradually develop cardiac dysfunction due to chron-
ic energy deﬁciency that is not triggered by catabolic derangements.
We also demonstrate that dietary interventions affect cardiac energy
production pathways. MCT cannot effectively supply VLCAD-deﬁcient
mice hearts with sufﬁcient energy long-term. Moreover, MCT-induced
lipotoxicity during energy steady state periods aggravates the cardiac
phenotype degenerating into diabetic-like dilated cardiomyopathy.
Similar but milder effects may also appear in asymptomatic patients if
supplemented continuously and long-term with an MCT diet when
not needed, althoughMCT is able to fully reverse cardiomyopathy if ap-
plied during catabolic situations [6]. The results of this study also show
that cardiacMRI andMRSmay be excellent tools to assessminor chang-
es in cardiac function and energetics in patients with β-oxidation de-
fects to initiate adequate preventive therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.02.001.
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